Costco Is a Magnificent Stock. Here's Why You Shouldn't Buy It Right Now
https://www.fool.com/investing/2024/03/24/costco-is-a-magnificent-stock-heres-why-you-should/?source=iedfolrf0000001
Mar 24, 2024 - Everyone knows about this top retail business, but its returns going forward might disappoint.
0
T+1 Is Wrong-Headed. Market Safety Is An Attitude, Not A Cost
https://seekingalpha.com/article/4680195-t-plus-1-is-wrong-headed-market-safety-is-an-attitude-not-a-cost?source=feed_all_articles
Mar 24, 2024 - Clearing and settlement should emphasize stability over transactions, prioritizing safety and limiting new positions for market stability.
0
Nissan unveils broad plan for strategic partnerships, 30 new models and EV cost effectiveness
https://seekingalpha.com/news/4083229-nissan-unveils-broad-plan-for-strategic-partnerships-30-new-models-and-ev-cost-effectiveness?source=feed_tag_japan
Mar 25, 2024 - Nissan Motor launched its Arc Plan aimed at driving value and profitability.
0
Prosperity Bancshares' (PB) Loan Pipeline Aids Amid High Costs
https://www.zacks.com/stock/news/2245556/prosperity-bancshares-pb-loan-pipeline-aids-amid-high-costs?cid=CS-ZC-FT-analyst_blog|zer_report_update-2245556
Mar 25, 2024 - Prosperity Bancshares' (PB) strong loans and deposit balance, and efforts to bolster fee income are likely to aid the top line. However, pressure on NIM, high costs and weak mortgage income are woes.
0
Eastman Chemical (EMN) Gains on Cost Cuts and Innovation
https://www.zacks.com/stock/news/2245564/eastman-chemical-emn-gains-on-cost-cuts-and-innovation?cid=CS-ZC-FT-analyst_blog|zer_report_update-2245564
Mar 25, 2024 - Eastman Chemical (EMN) benefits from cost-management actions, acquisitions and innovation amid challenges from soft demand and consumer de-stocking in certain markets.
0
Sen. Sanders goes after Novo Nordisk on a study on Ozempic low manufacture cost
https://seekingalpha.com/news/4084693-sanders-goes-after-novo-nordisk-study-ozempic-low-manufacture-cost?source=feed_sector_healthcare
Mar 27, 2024 - Novo Nordisk's diabetes drug, Ozempic, can cost as little as $5 a month to manufacture, but costs far more, prompting an uproar from Sen. Bernie Sanders. Read more here.
0
Indoor farms are remaking the produce market — at a cost to the planet
https://www.washingtonpost.com/climate-environment/2024/03/27/vertical-farms-climate-energy/
Mar 28, 2024 - High-tech greenhouses and vertical farms are a response to drought and other impacts of climate change. But the electricity they consume adds to the problem.
0
Keurig (KDP) Looks Poised on Growth Initiatives Amid High Costs
https://www.zacks.com/stock/news/2248627/keurig-kdp-looks-poised-on-growth-initiatives-amid-high-costs?cid=CS-ZC-FT-analyst_blog|rank_focused-2248627
Apr 01, 2024 - Keurig (KDP) is on growth track, thanks to its brand strength, innovation efforts, resilient category trends, market share gains and significant pricing actions.
0
Prestige Consumer (PBH) Banks on its Portfolio Amid Cost Woes
https://www.zacks.com/stock/news/2249012/prestige-consumer-pbh-banks-on-its-portfolio-amid-cost-woes?cid=CS-ZC-FT-analyst_blog|zer_report_update-2249012
Apr 02, 2024 - Prestige Consumer (PBH) develops long-term partnerships across its diverse retail footprint and invests heavily in the e-commerce channel.
0
SPHD: Too Low Dividend To Justify The Opportunity Cost
https://seekingalpha.com/article/4682151-sphd-invesco-s-and-p-500-high-dividend-volatility-too-low-justify-to-opportunity-cost-etf?source=feed_tag_etf_portfolio_strategy
Apr 04, 2024 - SPHD ETF focuses on high dividend-paying stocks that are further filtered based on the realized volatility levels. See why I think the fund is less attractive.
0